S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
about
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
description
clinical trial
@en
klinisch onderzoek
@nl
name
S1013: Validation of Cancer Qu ...... ab, or Erlotinib Hydrochloride
@en
type
label
S1013: Validation of Cancer Qu ...... ab, or Erlotinib Hydrochloride
@en
prefLabel
S1013: Validation of Cancer Qu ...... ab, or Erlotinib Hydrochloride
@en
P6153
P1476
S1013: A Prospective Study of ...... EGFRI-Induced Skin Toxicities
@en
P3098
NCT01416688
P580
2011-11-01T00:00:00Z
P582
2018-05-01T00:00:00Z